Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Oxytocin

Oxytocin is a nine-amino-acid peptide hormone; Health Canada lists marketed human oxytocin injections, and the reviewed U.S. label covers labour and postpartum use. In one paediatric autism trial, intranasal oxytocin did not differ significantly from placebo; social-memory findings come from mice.

Aliases reviewed
Sources checked
2026-10-28
Editorial status
published

Evidence at a glance

Human
LimitedOne randomized paediatric trial of an intranasal formulation outside the labelled use was reviewed.
Animal/cell
LimitedOne mouse knockout study, read as an abstract only.
Approved medicine
Approved product existsThree checked Canadian DPD records for marketed human products, plus one U.S. label

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.

Identity

Oxytocin is a nine-amino-acid peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, cyclic 1-6 disulfide; molecular formula C43H66N12O12S2). PubChem lists Pitocin and Syntocinon among its synonyms as trade names of labelled medicines. The labelled medicines reviewed here are sterile synthetic injection solutions with strength expressed in USP units, so they are not the same as a catalogue research material, whose identity, purity and formulation have not been verified.

Biological mechanism or research interest

Oxytocin is studied as a hormone whose labelled obstetric uses involve uterine contractions during and after labour, and separately as a signal involved in social behaviour. In the sources reviewed, the social-behaviour interest rests on mouse genetics: in male knockout mice, loss of the oxytocin gene impaired social memory, and exogenous oxytocin restored it. Social outcomes in people were tested in the randomized paediatric autism trial summarised below.

Verified approved human uses

Health Canada's Drug Product Database lists marketed human Oxytocin Injection, USP products. Three individually checked records are class Human and Marketed: Fresenius Kabi Canada (DIN 02139561), Hikma Canada (DIN 02550199, intravenous and intramuscular routes) and Pfizer Canada (DIN 00497398). The Canadian indication text was not reviewed, because these database records do not include it. The reviewed U.S. Fresenius Kabi label lists antepartum and postpartum obstetric uses, including medical (not elective) induction of labour and control of postpartum bleeding. These injection products do not establish approval or specifications for a catalogue research material.

Investigational human evidence

A 24-week randomized, placebo-controlled phase 2 trial assigned 290 children and adolescents aged 3 to 17 with autism spectrum disorder, at seven U.S. academic sites, to intranasal synthetic oxytocin or placebo. It found no significant between-group difference on the primary outcome, a modified social-withdrawal subscale of the Aberrant Behavior Checklist, or on secondary social and cognitive measures. The reviewed U.S. label concerns labelled obstetric injection use; it is not investigational evidence for other uses, routes or populations.

Popular claims that oxytocin improves bonding, trust, social anxiety, autism, libido or mood are not demonstrated human outcomes in the sources reviewed. The one paediatric autism trial reviewed found no significant difference from placebo on social or cognitive measures. The mouse social-memory findings concern genetic loss and restoration of oxytocin in rodents and do not show that a catalogue material changes social behaviour in people. The labelled obstetric uses do not support any of these claims.

Human versus animal or cell evidence

In male mice lacking the oxytocin gene, social memory failed to develop, while olfaction for non-social cues and spatial memory appeared intact. Oxytocin, but not vasopressin, restored social memory in the knockout mice, and an oxytocin antagonist produced a similar deficit in normal mice. This summary is based on the study abstract only. These rodent findings do not show the same effect in people, and the one randomized human trial reviewed found no significant difference from placebo on social measures.

Limitations and known risks

In obstetric use, the reviewed U.S. label warns of severe water intoxication with convulsions and coma, uterine hyperstimulation up to rupture, anaphylaxis, cardiac arrhythmia, and fetal bradycardia or permanent brain damage. In the paediatric intranasal trial, adverse-event incidence and severity were similar between the oxytocin and placebo groups; its detailed adverse-event tables were not reviewed here. Neither source establishes safety for other routes, populations or materials, and the catalogue material's identity, purity, sterility and route-specific safety are unverified.

What this profile is—and is not

Concise source review from primary and regulatory records, independently checked for source accuracy; supplier listings were used only to find the name. Recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.